As per the Annual Technology Vision Trends Report, 83% organisations are accelerating transformation, 99% are ranking the pandemic as an unprecedented stress test, and 100% are innovating with a call to action. Laggards must really catch up or they will be left behind, unravelled Ankur Aggarwal, MD, Technology, Accenture India.
Speaking at the Dataquest webinar on ‘Technology Vision for Life Sciences’, Aggarwal stressed that it is a once-in-a-generation re-platforming opportunity. “The window to do so is very small. Leaders will leap forward over laggards.”
Yes, pharma companies have been in the spotlight like never before in the last two years. But for them, the spotlight was on technology. The way in which and the place where they invest in technology are going through a visceral change.
Continue reading your story on the app
Continue reading your story in the magazine
Energy & Utility Sector Plugs Into New-Age Digital Solutions
As India gears up to meet the climate challenge, the energy sector is undergoing a radical transformation. Many new technologies will be crucial in this change
It's Time To Change! Here's How To Do It
The pandemic has been a great opportunity for radical transformation - of ourselves and our businesses. Here are some playbooks for an organisational change
Going Digital? Don't Forget To Build Cyber Citadels
As technologies get weaponised, users must adopt a multilayer approach that anticipates cyberattacks and safeguards critical assets before they are exploited
Choose the right metrics for your SaaS portfolio
With the onset of everything digital, organisations are applying datadriven techniques across their business processes to get that 5-star customer rating
OPEN THE BANK WINDOWS, PLEASE
Open banking is like a Pandora's Box that opens up many questions and disruptions, which both banks and their fintech neighbours need to face
How Al can come to the aid of farmers
Computer Vision, part of Al, can bring about radical changes in agriculture, increasing yields and incomes. It's time farming became a high-tech industry
Marching towards a multi-cloud future
While cloud has proved to be a major enabler for business continuity and transformation, as seen in the pandemic, it's time to step up to a multi-cloud phase
RAPIDLY CHANGING ENVIRONMENT REQUIRES ADAPTABILITY QUOTIENTW
While climate change and cyber-threats are keeping risk management experts busy, they are also aware of governance issues and the specific flip-side of hyper-personalisation for insurance companies. All this, when they are ready to embrace big data, Al and models to make their jobs faster and easier. Andrew D. Rallis, Global Chief Actuary, MetLife, and the immediate past president of the Society of Actuaries, gives some back-of-the-envelope calculations on the formula between technology and risk management in this interview. He also explains why it's time for not just IQ or EQ but also AQ. Excerpts:
POST-COVID WILL BE MORE FOCUSED ON CONTEXTUAL DATA SCIENCE
It is trying to fill a white space in the renewable space that not many have addressed so far. It manages over 5 GW of energy assets across the globe already. So what is it exactly that a sharper eye - or shall we say Alye - can do for a wind or solar energy park? P Rajasekaran, Chief Products Officer, Bahwan CyberTek helps us understand that while also covering some old and new challenges that surround Analytics. Excerpts from an interview:
Tech tips to keep supply chains moving
The pandemic has created a crisis for manufacturers around the world, affecting operations and supply chains. Thankfully, technology has solutions for each stage
Coming Out Of The Chemical Closet
Neuropsychopharmacologist Carl Hart says most of what the public knows about drugs is both scary and wrong.
Business at Its Best
With a big hand from the government, pharmaceutical companies delivered the vaccine that the world desperately needed. Here’s how something in 2020 went right for a change
Vintage Pharmacy Cabinet
An Homage to the Past by Embracing the Present.
We need covid-19 treatments asap—but a perverse incentive could slow pharma breakthroughs.
All Eyes On Gilead
Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. Gilead Sciences was ready
How Big Pharma Uses Charity Programs to Cover for Drug Price Hikes
How patient-assistance funds give drug companies cover to raise prices.
Under Fire From Washington, Pharma Is Fighting to Repair Its Reputation
As Washington considers limiting consumer pharmaceutical advertising, the industry tries to burnish its image.
It’s September and the grapes hang heavy on the vine, ripe for treading, explains Amy Jeffs
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry.
“WE PROVIDE SEAMLESS DATA INTEGRATION”
Umesh Pai, Managing Director, EPLAN Software & Services Pvt Ltd, speaks about how the company is addressing the requirements of digitalisation, standardisation and automation